Wafik El-Deiry: An outstanding day at Target Cancer Foundation’s Think Tank focused on rare cancers and precision medicine
Wafik El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared a post on LinkedIn:
“A truly outstanding day at Target Cancer Foundation’s Think Tank focused on rare cancers and precision medicine. A lot of ground was covered across an array of topics.”
Tempus AI, shared this post, adding:
“A fantastic meeting that discussed the needs and opportunities in rare cancer research and patient care. Rare cancer may be a misnomer: in aggregate rare cancer represents a significant portion of all cancers.
Tempus launched the Rare Cancer Initiative to work with foundations and researchers and make progress in these underserved communities.”
More posts featuring Wafik El-Deiry.
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget.
Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023